Abstract
β-Caryophyllene (BCP), a natural bicyclic sesquiterpene, is a selective phytocannabinoid agonist of type 2 receptors (CB2-R). It isn’t psychogenic due to the absence of an affinity to cannabinoid receptor type 1 (CB1). Among the various biological activities, BCP exerts anti-inflammatory action via inhibiting the main inflammatory mediators, such as inducible nitric oxide synthase (iNOS), Interleukin 1 beta (IL-1β), Interleukin-6 (IL-6), tumor necrosis factor-alfa (TNF-α), nuclear factor kapp a-light-chain-enhancer of activated B cells (NF-κB), cyclooxygenase 1 (COX-1), cyclooxygenase 2 (COX-2). Peroxisome proliferator-activated receptors alpha (PPAR-α) effects are also mediated by the activation of PPAR-α and PPAR-γ receptors. In detail, many studies, in vitro and in vivo, suggest that the treatment with β-caryophyllene improves the phenotype of animals used to model various inflammatory pathologies, such as nervous system diseases (Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke), atherosclerosis, and tumours (colon, breast, pancreas, lymphoma, melanoma and glioma cancer). Furthermore, pre-clinical data have highlighted that BCP is potentially useful in Streptococcus infections, osteoporosis, steatohepatitis, and exerts anticonvulsant, analgesic, myorelaxing, sedative, and antidepressive effects. BCP is non-toxic in rodents, with a Lethal dose, 50% (LD50) greater than 5000 mg/kg. Nevertheless, it inhibits various cytochrome P450 isoforms (above all, CYP3A4), which metabolise xenobiotics, leading to adverse effects, due to drug levels over therapeutic window. All the reported data have highlighted that both pharmacological and toxicological aspects need to be further investigated with clinical trials.
Highlights
Sesquiterpenoids are an extremely wide group of secondary metabolites found in the plant kingdom [1,2]
The aforementioned for maintaining an energetic balance, in the metabolism, and derivatives in the immune response. acid, The receptors are bound and activated by endogenous cannabinoids, of arachidonic aforementioned receptors are bound activated by endogenous better cannabinoids, of including
CB2-Rs are mainly found in peripheral tissues and in immune system cells (B and NK lymphocytes, macrophages, mast cells) and, to a lesser extent, in the central nervous system [13]
Summary
Sesquiterpenoids are an extremely wide group of secondary metabolites found in the plant kingdom [1,2]. Acid, The receptors are bound and activated by endogenous cannabinoids, of arachidonic aforementioned receptors are bound activated by endogenous better cannabinoids, of including Both receptors are bound by a lot of proteins in various pathways, acting as mediators of cellular as anandamide. Effects, not activating CB1-Rs (mainly expressed in the central nervous system, and in the liver, lungs, heart, blood vessels and digestive tract). CB2-Rs are mainly found in peripheral tissues and in immune system cells (B and NK lymphocytes, macrophages, mast cells) and, to a lesser extent, in the central nervous system (brain, neurons, microglia) [13]. BCPO lacks a double bond in position C4-C5 and it is not able to bind CB2-R [10]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have